EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Metformin hijacks AMPK-ERK1/2 signaling to trigger a pathogenic “selection trap” and thymic atrophy

Yilin Qian, Jingli Zhang, Shengqiu Liu, Yingyu Qin

Cell Reports · 2026-01 · 45 (1) · 116762

DOI: 10.1016/j.celrep.2025.116762 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Reports, 2026-01. Verfasst von Yilin Qian und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathogenic Biology and Immunology, Jiangsu Provincial Key Laboratory of Critical Care Medicine, School of Medicine, Southeast Universit…. Hauptthemen laut MEDLINE: Metformin, AMP-Activated Protein Kinases, Thymus Gland, MAP Kinase Signaling System. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metformin shows clinical promise beyond diabetes, yet its immunological safety in non-diabetic contexts remains uncertain. We found that metformin induces apoptosis in double-positive thymocytes across various mouse models and, importantly, creates a "selection trap" by promoting phenotypic maturation (TCRβ+CD69+) while simultaneously triggering their elimination. Mechanistically, this trap is sprung via mitochondrial dysfunction initiated by complex I inhibition, which causes ATP depletion and elevated mitochondrial reactive oxygen species. This metabolic stress drives sustained AMP-activated protein kinase (AMPK) activation, repurposing extracellular signal-regulated kinase 1/2 signaling to expose the BH3 domain of B cell lymphoma-2 (Bcl-2), thereby neutralizing its anti-apoptotic function. Transcriptomics further reveal that AMPK remodels metabolic pathways to augment oxidative injury and energy crisis, facilitating apoptosis. Notably, thymotoxicity persists even at subtherapeutic doses (25 mg/kg), challenging metformin's indiscriminate use in non-diabetic populations due to risks to central immune homeostasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminAMP-Activated Protein KinasesThymus GlandMAP Kinase Signaling SystemAnimalsMiceAtrophyMitochondriaApoptosisMice, Inbred C57BLThymocytesReactive Oxygen SpeciesProto-Oncogene Proteins c-bcl-2

Stichwörter der Autor:innen

AMPKBcl-2-BH3CP: Cell biologyCP: ImmunologyDP cellsERK1/2apoptosismetforminthymus

Substanzen

MetforminAMP-Activated Protein KinasesReactive Oxygen SpeciesProto-Oncogene Proteins c-bcl-2

Autor:innen und Institutionen

  • Department of Pathogenic Biology and Immunology, Jiangsu Provincial Key Laboratory of Critical Care Medicine, School of Medicine, Southeast University, Nanjing, Jiangsu, China.
  • Department of Pathogenic Biology and Immunology, School of Medicine, Southeast University, Nanjing, Jiangsu, China.
  • Department of Pathogenic Biology and Immunology, Jiangsu Provincial Key Laboratory of Critical Care Medicine, School of Medicine, Southeast University, Nanjing, Jiangsu, China. Electronic address: yyqin@seu.edu.cn.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Qian, Y., Zhang, J., Liu, S., & Qin, Y. (2026). Metformin hijacks AMPK-ERK1/2 signaling to trigger a pathogenic “selection trap” and thymic atrophy. Cell Reports, 45(1), 116762. https://doi.org/10.1016/j.celrep.2025.116762

Vancouver

Qian Y, Zhang J, Liu S, Qin Y. Metformin hijacks AMPK-ERK1/2 signaling to trigger a pathogenic “selection trap” and thymic atrophy. Cell Reports. 2026;45(1):116762. doi:10.1016/j.celrep.2025.116762

BibTeX
@article{Qian2026,
  author = {Qian, Yilin and Zhang, Jingli and Liu, Shengqiu and Qin, Yingyu},
  title = {Metformin hijacks AMPK-ERK1/2 signaling to trigger a pathogenic “selection trap” and thymic atrophy},
  journal = {Cell Reports},
  year = {2026},
  volume = {45},
  number = {1},
  pages = {116762},
  doi = {10.1016/j.celrep.2025.116762}
}
Kostenlos starten →